Professor Marco Gerlinger



95-97 Harley Street London, W1G 6AF T +44 (0) 20 7317 2500 www.theloc.com

Jennifer Hills E. gerlingerpa@hcahealthcare.co.uk T. 0207 317 2562

22 August 2024

Dr. Anita Bhasi Shrewsbury Road Surgery Forest Gate London E7 8QP shrewsburyroadsurgery@nhs.net

Dear Dr Bhasi,

Diagnosis and treatment:

Jan 2024: Metastatic (liver) sigmoid adenocarcinoma, MMRp, RAS/BRAF wild type

March 2024: started FOLFIRI chemotherapy while RAS/BRAF status was pending, not a surgical candidate as per ST Barts HPB MDT

April 2024: escalated to FOLFIRI Cetuximab after tumour has been confirmed to be RAS and BRAF wild type, TMB = 6

June 2024: excellent response after 7 cycles of FOLFIRI, Cetuximab on CT, MRI liver and PET CT with no new signs of disease.

July 2024: Surgical removal of primary tumour and of multiple liver metastases under Mr. Yip and Mr. Chan.

I have seen Jialin in my clinic today for the results of a restaging CT scan. He had his operation in July and has recovered well. The wound is almost completely healed. He currently has a stoma with a plan to reverse this once he has completed chemotherapy. He had to change the bag up to every two hours but he now has Loperamide tablets to slow this down. We discussed the scan results. This shows the multiple resections and the RFA site in the liver and there is now no further evidence of disease. In addition, the CEA tumour marker test he had on 8.8.24 shows that this is within the normal range. This is overall excellent news. I have explained to Jialin that I would like to give 5 more cycles of Folfiri Cetuximab to bring the total cycle number up to 12 which is in line with the ESMO guidelines for patients who have resection of liver metastases. He is happy with this plan and I will try to schedule the next cycle of chemotherapy for the 6.9.24, which is in two weeks. This will allow the wound to completely heal. I will also arrange a repeat MRI of the liver in the meantime as a new baseline test to compare to in the future. We had a brief discussion about the prognosis. There is still a relatively high risk that the tumour will come back at some point. These extra few cycles of chemotherapy should reduce this and he will subsequently need close follow up with scans every three months and regular bloods. I will arrange the restart of chemotherapy and will see Jialin after he had the first cycle.

Yours sincerely,

Professor Marco Gerlinger

cc: Mr Jialin Yang Flat 48 Cornwell House 13 Ron Leighton Way London

E6 1EQ - Email: zakkyang@hotmail.com

Mr Vincent S Yip secretary@vincentyip.co.uk